Skip to main content
Premium Trial:

Request an Annual Quote

With Dwindling Q2 Revenues, Pyrosequencing Announces Cost-Cutting Plan

NEW YORK, Aug. 8-With sharply declining revenues and wider losses for the second quarter of 2002, Pyrosequencing today announced a company-wide plan to slash monthly costs by 10 percent.


The Swedish genetic analysis equipment company reported revenues of $1.8 million in the quarter, down from $2.7 million in the second quarter of 2001.


During the quarter, the company took orders for 24 new DNA analysis systems, recording 13 as revenue. The company also said it has a backlog of 13 systems and therefore expects revenues to climb in subsequent quarters.


Net losses for the quarter were $5.5 million or $0.16 per share. In the equivalent quarter during the previous year, losses were $3.8 million or $0.11 per share.


R&D expenses climbed from $2.6 million in the second quarter of 2001 to just over $3 million in the second quarter of 2002.


Its cost-cutting plan will "adjust spending to reflect current market conditions," the company said in a statement. Pyrosequencing expects that charges resulting from this effort will amount to less than $200,000.


Pyrosequencing held cash and short-term investments worth $19.1 million as of June 30, 2002.


For more information, see the company press release.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.